Milrinone Lactate NDC 63323-617

NDC codes

FDA NDC Directory

Product NDC (as listed)63323-617Labeler and product segments. Claims need a package NDC.

Product NDC at billing width63323-0617Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
63323-617-10	63323061710	10 VIAL, SINGLE-DOSE in 1 TRAY (63323-617-10) / 10 mL in 1 VIAL, SINGLE-DOSE (63323-617-01)Marketed from Aug 1, 2002
63323-617-20	63323061720	10 VIAL, SINGLE-DOSE in 1 TRAY (63323-617-20) / 20 mL in 1 VIAL, SINGLE-DOSE (63323-617-02)Marketed from Aug 1, 2002
63323-617-50	63323061750	1 VIAL, SINGLE-DOSE in 1 CARTON (63323-617-50) / 50 mL in 1 VIAL, SINGLE-DOSEMarketed from Aug 1, 2002

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Milrinone Lactate
Generic name (nonproprietary): milrinone lactate
Active ingredients: Milrinone lactate — 1 mg/mL
Dosage form: Injection, Solution
Route: Intravenous
Labeler: Fresenius Kabi USA, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 075936
Marketing start: Aug 1, 2002
Listing expires: Dec 31, 2026
Other FDA classes: Phosphodiesterase 3 Inhibitors (Mechanism)
Identifiers: Product ID 63323-617_7ada1876-c47a-4e3e-bd48-a6a1f486b517SPL ID 7ada1876-c47a-4e3e-bd48-a6a1f486b517SPL set ID ac43ba6b-635d-4129-8eea-96f3f5a4785eRxCUI 1791854, 1791859, 1791861UNII 9K8XR81MO8UPC 0363323617509, 0363323617028, 0363323617011
Pharmacologic class: Phosphodiesterase 3 Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N463323061710 followed by a unit qualifier and the quantity

Package 63323-0617-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 17, 2023.

Indications (excerpt from the label)

INDICATIONS AND USAGE: Milrinone lactate injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. Patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. The facility for immediate treatment of potential cardiac events, which may include life threatening ventricular arrhythmias, must be available. The majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)